Recursion Pharmaceuticals Inc (RXRX)
9.76
+0.25
(+2.63%)
USD |
NASDAQ |
May 20, 15:09
Recursion Pharmaceuticals Cash from Operations (Annual): -287.78M for Dec. 31, 2023
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | -287.78M |
| December 31, 2022 | -83.52M |
| December 31, 2021 | -158.61M |
| Date | Value |
|---|---|
| December 31, 2020 | -45.40M |
| December 31, 2019 | -57.04M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Annual) Range, Past 5 Years
-287.78M
Minimum
2023
-45.40M
Maximum
2020
-126.47M
Average
-83.52M
Median
2022
Cash from Operations (Annual) Benchmarks
| Eli Lilly and Co | 4.240B |
| Absci Corp | -64.64M |
| Palatin Technologies Inc | -28.42M |
| Oragenics Inc | -7.291M |
| Actinium Pharmaceuticals Inc | -47.34M |